Treatment of Primary Human Immunodeficiency Virus Type 1 Infection with Potent Antiretroviral Therapy Reduces Frequency of Rapid Progression to AIDS

Berrey, M. Michelle; Schacker, Timothy; Collier, Ann C.; Shea, Theresa; Brodie, Scott J.; Mayers, Douglas; Coombs, Robert; Krieger, John; Chun, Tae-Wook; Fauci, Anthony; Self, Steven G.; Corey, Lawrence
May 2001
Journal of Infectious Diseases;5/15/2001, Vol. 183 Issue 10, p1466
Academic Journal
Discusses the clinical benefits of antiretroviral therapy in primary HIV type 1 infection. Virologic response to antiretroviral therapy; Effect of combination antiretroviral therapy on CD4... T cells; Adverse events and adherence to medications.


Related Articles

  • T Cell Dynamics and the Response to HAART in a Cohort of HIV-1-Infected Elite Suppressors. Sedaghat, Ahmad R.; Rastegar, Darius A.; O'Connell, Karen A.; Dinoso, Jason B.; Wilke, Claus O.; Blankson, Joel N. // Clinical Infectious Diseases;12/1/2009, Vol. 49 Issue 11, p1763 

    Elite controllers or suppressors are untreated human immunodeficiency virus type 1 (HIV-1)-infected patients who maintain undetectable viral loads. In this study, we show that most elite suppressors do not experience significant changes in T cell counts over a 10-year period. Interestingly,...

  • Activity of the Combination of Nelfinavir and Saquinavir Against Human Immunodeficiency Virus After Failure of Prior Protease Inhibitor Therapy. Kravcik, Stephen; Victor, Gary; Angel, Jonathan B.; Badley, Andrew D.; Cameron, D. William // Clinical Infectious Diseases;9/1/1999, Vol. 29 Issue 3, p702 

    Reports on the effectiveness of combining nelfinavir and saquinavir for the treatment of HIV infections. Details of a retrospective study on HIV-positive patients prescribed with nelfinavir and saquinavir; Effects of the drugs on the viral levels of the patients; Importance of treatment changes...

  • A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1. Saag, Michael; Goodrich, James; Fätkenheuer, Gerd; Clotet, Bonaventura; Clumeck, Nathan; Sullivan, John; Westby, Mike; van der Ryst, Elna; Mayer, Howard // Journal of Infectious Diseases;6/1/2009, Vol. 199 Issue 11, p1638 

    Background. Maraviroc, a CCR5 antagonist, is active against R5 but not X4 or dual- or mixed-tropic strains of human immunodeficiency virus type 1 (HIV-1). A phase 2b study was conducted to determine the safety and efficacy of maraviroc in combination with optimized background therapy in...

  • Additional Reports of Failure to Respond to Treatment After Rabies Exposure in Thailand. Hemachudha, Thiravat; Mitrabhakdi, Erawady; Wilde, Henry; Vejabhuti, Apirom; Siripataravanit, Somporn; Kingnate, Darika // Clinical Infectious Diseases;1/1/1999, Vol. 28 Issue 1, p143 

    Focuses on additional reports of failure to respond to treatment after rabies exposure in Thailand. Deviations from treatment recommendations; Autopsy-confirmed deaths due to rabies; Postexposure rabies treatment.

  • AIDS: A Review of Targets and Approaches for Treatment. Gupta, S. D.; Ramteke, Suman; Gupta, A.; Moorthy, N. S. H. N. // Indian Journal of Pharmaceutical Sciences;2007, Vol. 69 Issue 2, p173 

    Untreated HIV infection is characterized by a gradual deterioration of immune function. Most notably, crucial immune cells known as CD4 positive T lymphocytes are disabled and killed during the typical course of infection. These T lymphocyte cells play central role in the immune response. The...

  • Are We Done Monkeying Around With TRIM5α? Campbell, Edward // Molecular Therapy;Jun2014, Vol. 22 Issue 6, p1072 

    The author discusses aspects of the stabilization of human tripartite motif-containing protein 5 (TRIM5) alpha protein which restrict the human immunodeficiency virus (HIV-1) infection in human T cells. He states that TRIM5 alpha has the ability to inhibit the infection between the member of...

  • Science Translational Medicine: Genetically modified T cell therapy shown to be safe, lasting in decade-long study of HIV patients.  // Biomedical Market Newsletter;5/7/2012, Vol. 21, p1 

    The article offers information on the report published in Science Translational Medicine regarding the treatment of patients infected with Human Immunodeficiency Virus (HIV) with genetically modified T cell therapy.

  • Stabilized Human TRIM5α Protects Human T Cells From HIV-1 Infection. Richardson, Max W; Guo, Lili; Xin, Frances; Yang, Xiaolu; Riley, James L // Molecular Therapy;Jun2014, Vol. 22 Issue 6, p1084 

    Rhesus (rh) but not human (hu) TRIM5α potently restricts human immunodeficiency virus (HIV)-1 infection. It is not clear why huTRIM5α fails to effectively block HIV infection, but it is thought to have a lower affinity for the viral core. Using primary human CD4 T cells, we investigated...

  • TO THE EDITOR. Freeman, Michael L.; Mudd, Joseph C.; Shive, Carey L.; Younes, Souheil-Antoine; Panigrahi, Soumya; Sieg, Scott F.; Lee, Sulggi A.; Hunt, Peter W.; Calabrese, Leonard H.; Gianella, Sara; Rodriguez, Benigno; Lederman, Michael M. // Clinical Infectious Diseases;6/1/2016, Vol. 62 Issue 11, p1468 

    A response from the authors of the article "CD8 T-cell expansion and inflammation linked to CMV coinfection in ART-treated HIV infection" in the 2016 issue is presented.

  • Proliferative Responses to Human Immunodeficiency Virus Type 1 (HIV-1) Antigens in HIV-1-Infected Patients with Immune Reconstitution. Blankson, Joel N.; Gallant, Joel E.; Siliciano, Robert F. // Journal of Infectious Diseases;2/15/2001, Vol. 183 Issue 4, p657 

    Features a study on human immunodeficiency virus type 1 (HIV-1)-specific CD4 T cell proliferative responses in HIV-1-infected patients who began highly active antiretroviral therapy with low CD4 cell count nadirs and experienced immune reconstitution. Background of the CD4 T cells; Patients and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics